MedTrace Logo

Cerebral Atherosclerosis Research With Positron Emission Tomography

NCT07041372 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 310

Last updated 2025-06-27

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are:

* Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors?
* Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients.

Participants will:

* Undergo whole-body FDG PET once their neurological status has stabilized after stroke.
* Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day.
* Maintain regular clinic visits for up to 24 months following the index stroke

Conditions

  • Cerebral Infarction

Interventions

DIAGNOSTIC_TEST

FDG-PET

The participants undergo whole-body FDG PET once their neurological status has stabilized after stroke.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-22
Primary Completion
2029-02-28
Completion
2029-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07041372 on ClinicalTrials.gov